Alternative agents for anti-inflammatory treatment of asthma

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 4 SUPPL., 1998, Pages

  Szefler, Stanley J ^a   Nelson, Harold S ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Beclomethasone; Budesonide; Cromolyn; Glucocorticoids; Leukotriene; Montelukast; Nedocromil; Theophylline; Zafirlukast; Zileuton

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; FLUTICASONE; LEUKOTRIENE D4; LEUKOTRIENE E4; METHYLXANTHINE; NEDOCROMIL; SALMETEROL; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CORTICOSTEROID THERAPY; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS;

EID: 0031737265     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70003-X     Document Type: Article

References (85)

1. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): NIH/National Heart, Lung, and Blood Institute; April 1997. Publication No. 97-4051.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Bethesda (MD): NIH/National Heart, Lung, and Blood Institute; 1991. Publication No. 91-3042.
3. Eigen H, Reid JJ, Dahl R, Del Bufalo G, Fasano L, Gunella G, et al. Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma. J Allergy Clin Immunol 1987;80:612-21.
4. Blumenthal MN, Selcow J, Spector S, Zeiger RS, Mellon M. A multi-center evaluation of the clinical benefits of cromolyn sodium aerosol by metered-dose inhaler in the treatment of asthma. J Allergy Clin Immunol 1988;81:681-7.
5. Petty TL, Rollins DR, Christopher K, Good JT, Oakley R. Cromolyn sodium is effective in adult chronic asthmatics. Am Rev Respir Dis 1989;139:694-701.
6. Löwhagen O, Rak S. Modification of bronchial hyperreactivity after treatment with sodium cromoglycate during pollen season. J Allergy Clin Immunol 1985;75:460-7.
7. Hoshino M, Nakamura Y. The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics. Eur Respir J 1997;10:858-65.
8. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987;79:734-40.
9. Fyans PG, Chatterjee PC, Chatterjee SS. A trial comparing nedocromil sodium (Tilade®) and placebo in the management of bronchial asthma. Clin Allergy 1986;16:505-11.
10. Rebuck AS, Kesten S, Boulet LP, Cartier A, Cockcroft D, Gruber J, et al. A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group. J Allergy Clin Immunol 1990;85:612-7.
11. North American Tilade Study Group. A double-blind multicenter group comparative study of the efficacy and safety of nedocromil sodium in the management of asthma. Chest 1990;97:1299-306.
12. Schwartz HJ, Blumenthal M, Brady R, Braun S, Lockey R, Myers D, et al. A comparative study of the clinical efficacy of nedocromil sodium and placebo: How does cromolyn sodium compare as an active control treatment? Chest 1996;109:945-52.
13. Lal S, Dorow PD, Venho KK, Chatterjee SS. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993;104:438-47.
14. Leung KBP, Flint KC, Brostoff J, Hudspith BN, Johnson NM, Pearce FL. A comparison of nedocromil sodium and sodium cromoglycate on human lung mast cells obtained by bronchoalveolar lavage and by dispersion of lung fragments. Eur J Respir Dis 1986;69(suppl 147):223-6.
15. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: Time for reappraisal? Eur Respir J 1994;7:579-91.
16. Ward AJM, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline - an immunomodulatory role in asthma? Am Rev Respir Dis 1993;147:518-23.
17. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffrey P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-8.
18. Dutoit JI, Salome CM, Woolcock AJ. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. Am Rev Respir Dis 1987;136:1174-8.
19. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma: demonstration by with-drawal of therapy. Am J Respir Crit Care Med 1995;151:1907-14.
20. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 1995;8:831-3.
21. 2-agonists: inhibition of TNF-α release from human mast cells. J Allergy Clin Immunol 1997;100:825-31.
22. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994;150:1006-11.
23. Kraft M, Wenzel SE, Bettinger CM, Martin RJ. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997;111:1249-54.
24. 2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J 1997;10:1483-8.
25. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
26. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
27. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
28. 4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-53.
29. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonists, ICI 204,219, on and gen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-5.
30. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
31. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
32. 4 antagonist, L-648,051. Allergy 1992;47:604-9.
33. Kane GC, Pollice M, Kim C-J, Cohn J, Dworski RT, Murray JJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996;97:646-54.
34. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate™ (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995;151:A42.
35. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995;152:897-905.
36. Fischer AR, McFadden CA, Frantz R, Awni WM, Cohn J, Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152:1203-7.
37. Liu MC, Dubé LM, Lancaster J, The Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996;98:859-71.
38. Svendsen UG, Frølund L, Madsen F, Nielsen NH, Holstein-Rathlou N-H, Weeke B. A comparison of the effects of sodium cromoglycate and beclomethasone dipropionate on pulmonary function and bronchial hyperreactivity in subjects with asthma. J Allergy Clin Immunol 1987;80:68-74.
39. Kraemer R, Sennhauser F, Reinhardt M. Effects of regular inhalation of beclomethasone dipropionate and sodium cromoglycate on bronchial hyperreactivity in asthmatic children. Acta Paediatr Scand 1987;76:119-23.
40. Shapiro GG, Sharpe M, DeRouen TA, Pierson WE, Furukawa CT, Virant FS, et al. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol 1991;88:742-8.
41. Price JF, Weller PH. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir Med 1995;89:363-8.
42. Faurschou P, Bing J, Edman G, Engel A-M. Comparison between sodium cromoglycate (MDI: metered-dose inhaler) and beclomethasone dipropionate (MDI) in treatment of adult patients with mild to moderate bronchial asthma: a double-blind, double-dummy randomized, parallel-group study. Allergy 1994;49:659-63.
43. Molema J, van Herwaarden CLA, Folgering HThM. Effects of long-term treatment with inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with allergic asthma. Eur Respir J 1989;2:308-16.
44. Francis RS, McEnery G. Disodium cromoglycate compared with beclomethasone dipropionate in juvenile asthma. Clin Allergy 1984;14:537-40.
45. Ng SH, Dash CH, Savage SJ. Betamethasone valerate compared with sodium cromoglycate in asthmatic children. Postgrad Med J 1977;53:315-20.
46. Sarsfield JK, Sugden E. A comparative study of betamethasone valerate aerosol and sodium cromoglycate in children with severe asthma. Practitioner 1977;218:128-32.
47. Mitchell I, Paterson IC, Cameron SJ, Grant IWB. Treatment of childhood asthma with sodium cromoglycate and beclomethasone dipropionate aerosol singly and in combination. Br Med J 1976;2:457-8.
48. Orefice U, Struzzo P, Dorigo R, Peratoner A. Long-term treatment with sodium cromoglycate, nedocromil sodium and beclomethasone dipropionate reduces bronchial hyperresponsiveness in asthmatic subjects. Respiration 1992;59:97-101.
49. Bel EH, Timmers MC, Hermans J, Dijkman JH, Sterk PJ. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis 1990;141:21-8.
50. Svendsen UG, Frølund L, Madsen F, Nielsen NH. A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma. J Allergy Clin Immunol 1989;84:224-31.
51. Harper GD, Neill P, Vathenen AS, Cookson JB, Ebden P. A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma. Respir Med 1990;84:463-9.
52. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. J Allergy Clin Immunol 1998;101:14-23.
53. Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann Allergy Asthma Immunol 1996;77:112-8.
54. Simons FER, The Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
55. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF, The Dutch Paediatric Asthma Study Group. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-95.
56. Ind PW, Johnson M, Heinzer M. Leukotriene antagonists and inhaled corticosteroids: clinical efficacy and pharmacoeconomic comparisons [abstract]. Am J Respir Crit Care Med 1998;157:A415.
57. Wenzel S, Chervinsky P, Kerwin E, Silvers W, Faiferman I, Dubb J. Oral pranlukast (Ultair™) vs inhaled beclomethasone: results of a 12-week trial in patients with asthma [abstract]. Am J Respir Crit Care Med 1997;155:A203.
58. Knorr BA, Matz J, Sveum RJ, Becker AB, Reiss TF, Seidenberg BC, et al. Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year old patients [abstract]. Eur Respir J 1997;10(suppl 25):219s.
59. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment [abstract], Eur Respir J 1997;10(suppl 25):437s.
60. 2-agonists [abstract], Eur Respir J 1997;10(suppl 25):419s.
61. Westbroek J, Pasma HR. The effect of inhaled fluticasone propionate (FP) 100 μg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthmatics [abstract], Eur Respir J 1997;10(suppl 25):243s.
62. Chervinsky P, Wenzel S, Kerwin E, Silvers W, Juniper E, Richner R. Pranlukast, a leukotriene receptor antagonist, improves quality of life in adult asthma patients [abstract]. Eur Respir J 1997;10(suppl 25):439s.
63. Toogood JH, Jennings B, Lefcoe NM. A clinical trial of combined cromolyn/beclomethasone treatment for chronic asthma. J Pediatr 1981;67:317-24.
64. Löwhagen O, Rak S. Effect of sodium cromoglycate and budesonide on bronchial hyperreactivity in nonatopic asthmatics. Respiration 1984;46:105.
65. Dawood AG, Hendry AT, Walker SR. The combined use of betamethasone valerate and sodium cromoglycate in the treatment of asthma. Clin Allergy 1977;7:161-5.
66. Killer EJ, Milner AD. Betamethasone 17 valerate aerosol and disodium cromoglycate in severe childhood asthma. Br J Dis Chest 1975;69:103-6.
67. Svendsen UG, Jørgensen H. Inhaled nedocromil sodium as additional treatment to high dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J 1991;4:992-9.
68. O'Hickey SP, Rees PJ. High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma. Respir Med 1994;88:499-502.
69. Wong CS, Cooper S, Britton JR, Tattersfield AE. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy 1993;23:370-6.
70. Goldin JG, Bateman ED. Does nedocromil sodium have a steroid sparing effect in adult asthmatic patients requiring maintenance oral corticosteroids? Thorax 1988;43:982-6.
71. Boulet L-P, Cartier A, Cockcroft DW, Gruber JM, Laberge F, MacDonald GF, et al. Tolerance to reduction of oral steroid dosage in severely asthmatic patients receiving nedocromil sodium. Respir Med 1990;84:317-23.
72. Marin JM, Carrizo SJ, Garcia R, Ejea MV. Effects of nedocromil sodium in steroid-resistant asthma: a randomized controlled trial. J Allergy Clin Immunol 1996;97:602-10.
73. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981;304:71-5.
74. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
75. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
76. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
77. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
78. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997;155:1235-40.
79. Nayak AS, Anderson P, Charous BL, Williams K, Simonson S. Equivalence of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low-dose inhaled corticosteroids [abstract]. J Allergy Clin Immunol 1998;101:S233.
80. Gottlieb DJ, Beiser AS, O'Connor GT. Poverty, race, and medication use are correlates of asthma hospitalization rates: a small area analysis in Boston. Chest 1995;108:28-35.
81. Vollmer WM, O'Hollaren M, Ettinger KM, Stibolt T, Wilkins J, Buist AS, et al. Specialty differences in the management of asthma: a cross-sectional assessment of allergists' patients and generalists' patients in a large HMO. Arch Intern Med 1997;157:1201-8.
82. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91.
83. Wennergren G, Kristjánsson S, Strannegård I-L. Decrease in hospitalization for treatment of childhood asthma with increased use of anti-inflammatory treatment, despite an increase in the prevalence of asthma. J Allergy Clin Immunol 1996;97:742-8.
84. Ernst P, Spitzer WO, Suissa S, Cockcroft D, Habbick B, Horwitz RI, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992;268:3462-4.
85. Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. Br Med J 1997;314:1439-41.